GILD Jun 2025 62.500 call
| Previous Close | 22.60 |
| Open | 22.60 |
| Bid | 22.15 |
| Ask | 23.05 |
| Strike | 62.50 |
| Expire Date | 2025-06-20 |
| Day's Range | 22.60 - 22.60 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 27 |
ZacksGILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
PR NewswireHetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to
